Health In Tech Announces Closing of $7.0 Million Private Placement

Rhea-AI Summary

Health In Tech (Nasdaq: HIT) closed a private placement on March 27, 2026, raising approximately $7.0 million in gross proceeds by issuing 5,600,000 shares of common stock at $1.25 per share.

Net proceeds will fund sales distribution expansion, technology and product development, and general corporate purposes; resale registration rights were agreed with PIPE investors.

Positive

• Gross proceeds of $7.0 million
• Issued 5,600,000 common shares at $1.25 per share
• New institutional investors added to shareholder base
• Agreed to file a resale registration statement for PIPE shares

Negative

• Proceeds reported before placement agent fees and offering expenses
• Securities were sold in a private placement and are not registered, limiting resale until registration effectiveness

News Market Reaction – HIT

-6.47%

11 alerts

-6.47% Session close to close

-19.6% Trough in 5 hr 51 min

$91.74M Market Cap

0.7x Rel. Volume

In the Mar 30 session, HIT declined 6.47%, reflecting a notable negative market reaction. Argus tracked a trough of -19.6% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -6.5% in the session following this news. A negative reaction despite the stated gro...

Analysis

The stock moved -6.5% in the session following this news. A negative reaction despite the stated growth uses for the $7.0 million raise fits prior trading around the original PIPE announcement, which saw a -11.05% move on Mar 25. The deal adds 5,600,000 new shares at $1.25, so dilution concerns may dominate near term sentiment. Future updates on deployment of proceeds and revenue traction could be important for reassessing the impact.

Key Figures

Gross proceeds: $7.0 million Shares issued: 5,600,000 shares PIPE price: $1.25 per share +1 more

4 metrics

Gross proceeds $7.0 million PIPE private placement before fees and expenses

Shares issued 5,600,000 shares Common stock issued in the PIPE

PIPE price $1.25 per share Offering price for PIPE investors

Securities Act section Section 4(a)(2) Exemption used for private placement under Securities Act of 1933

Previous Private placement Reports

1 past event · Latest: Mar 25 (Negative)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 25	Private placement deal	Negative	-11.1%	Announced $7.0M PIPE at $1.25 per share, triggering an 11.05% drop.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The only prior private placement headline in the last six months coincided with a double-digit price decline, indicating that equity financings have been met with selling pressure.

Recent Company History

Over recent months, Health In Tech has combined rapid growth with capital markets activity. On Mar 25, it announced a $7.0 million PIPE at $1.25, which saw the stock fall 11.05%. That deal followed strong 2025 results, guidance for $45–$50 million 2026 revenue, and AI-focused partnerships and leadership moves. Today’s closing of the PIPE formalizes that previously announced financing and its intended uses.

Key Terms

private placement, PIPE, Section 4(a)(2), Regulation D, +4 more

8 terms

private placement financial

"Health In Tech Announces Closing of $7.0 Million Private Placement"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

PIPE financial

"the closing of its previously announced private investment in public equity financing (the "PIPE")"

A PIPE (private investment in public equity) is a deal in which institutional or accredited investors buy shares or convertible securities directly from a publicly traded company, usually at a discount to the market price. Companies use PIPEs to raise money faster than through a traditional public offering; for existing shareholders they matter because the newly issued shares add to the share count and can dilute ownership.

Section 4(a)(2) regulatory

"offered in a private placement under Section 4(a)(2) of the Securities Act of 1933"

Section 4(a)(2) is a part of U.S. securities laws that allows companies to sell their stock directly to certain investors without registering the sale with regulators. This process is often used for private placements, making it easier and faster for companies to raise money from knowledgeable or institutional investors. It matters to investors because it provides an alternative way to buy shares, often with fewer disclosures and lower costs.

Regulation D regulatory

"and/or Regulation D promulgated thereunder, and have not been registered"

Regulation D is a set of rules that govern how companies can raise money from investors without going through the full process required for public stock offerings. It provides simplified options for private placements, making it easier for companies to seek investments from a smaller group of investors. For investors, it offers opportunities to invest in private companies, often with fewer restrictions, but also with different levels of risk and disclosure.

registration rights agreement regulatory

"Pursuant to a registration rights agreement with the PIPE investors"

A registration rights agreement is a contract that gives investors the option to have their ownership stakes officially registered with the government, making it easier to sell their shares later. This agreement matters because it provides investors with a clearer path to cash out their investments if they choose, offering more liquidity and confidence in their ability to sell their holdings when desired.

resale registration statement regulatory

"agreed to file a resale registration statement with the Securities and Exchange Commission"

A resale registration statement is a document filed with regulators that allows existing shareholders to sell their shares to the public. It provides the necessary legal approval and information for these shares to be resold on the market, helping to increase the availability of shares for trading. For investors, it signals that shares held by current owners can be offered for sale, potentially affecting share prices and market liquidity.

forward-looking statements regulatory

"Certain statements in this press release are forward-looking statements"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

U.S. Private Securities Litigation Reform Act of 1995 regulatory

"for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995"

A federal law that changed the rules for suing companies over securities claims by making it harder to bring class-action lawsuits and by protecting certain forward-looking statements. Think of it as a rulebook that raises the bar for plaintiffs to show clear evidence of wrongdoing and gives companies limited shelter for predictions, which matters to investors because it can reduce litigation risk, legal costs, and volatility tied to lawsuit headlines.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

STUART, Fla., March 27, 2026 /PRNewswire/ -- Health In Tech, Inc. (Nasdaq: HIT) ("Health In Tech" or the "Company"), an AI-enabled InsurTech platform company, today announced the closing of its previously announced private investment in public equity financing (the "PIPE"), resulting in gross proceeds of approximately $7.0 million before deducting placement agent fees and offering expenses.

The PIPE included participation from institutional investors and accredited investors. The Company issued an aggregate of 5,600,000 shares of common stock at a price of $1.25 per share.

Craig-Hallum Capital Group LLC acted as the sole placement agent for the PIPE. Loeb & Loeb LLP acted as counsel to the Company. Faegre Drinker Biddle & Reath LLP acted as counsel to the placement agent.

Strengthening Financial Flexibility to Support Strategic Growth

"This financing strengthens our ability to accelerate the next phase of our platform development," said Tim Johnson, Chief Executive Officer of Health In Tech. "The additional capital will support key technology initiatives and help us bring new product capabilities to market that our clients have been actively requesting. As we continue expanding the functionality of our platform, we believe it will deepen customer engagement and support sustained, scalable revenue growth."

Use of Proceeds

The Company intends to use the net proceeds from the private placement for:

• Expansion of sales distribution
• Advance technology development
• Support new product development
• General corporate purposes and working capital

"In addition, the transaction introduces new long-term institutional investors to our shareholder base," said Julia Qian, Chief Financial Officer of Health In Tech. "We believe this will enhance market visibility and support our broader capital markets strategy while providing flexibility to continue investing in our technology and growth initiatives."

The securities described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and/or Regulation D promulgated thereunder, and have not been registered under the Securities Act or applicable state securities laws. Accordingly, the securities issued in the PIPE may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Pursuant to a registration rights agreement with the PIPE investors, the Company has agreed to file a resale registration statement with the Securities and Exchange Commission registering the resale of the shares of Class A common stock described above.

Use of Forward-Looking Statements

Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about Health In Tech's possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as "may," "will," "should," "design," "target," "aim," "hope," "expect," "could," "intend," "plan," "anticipate," "estimate," "believe," "continue," "predict," "project," "potential," "goal," or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to Health In Tech's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause Health In Tech's actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond Health In Tech's control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects Health In Tech's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to Health In Tech's operations, results of operations, growth strategy and liquidity. Health In Tech undertakes no obligation to update any forward-looking statements, except as required by law.

About Health In Tech 

Health In Tech, Inc. (Nasdaq: "HIT") is an AI-enabled InsurTech platform company, which offers a marketplace that improves processes in the health insurance industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies, licensed brokers, Managing General Underwriter (MGUs) and third-party administrators ("TPAs"). Health In Tech's platform serves as a marketplace for brokers, TPAs, MGUs and carriers to access self-funded health insurance for employers, providing functions including customized self-funded health plans, bindable stop-loss quotes, AI-enabled underwriting, claims administration and reporting integration.

Investor Contact:
Health In Tech Investor Relations
ir@healthintech.com

The Equity Group
Kalle Ahl, CFA
T: (303) 953-9878
kahl@theequitygroup.com

Devin Sullivan, Managing Director
dsullivan@theequitygroup.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/health-in-tech-announces-closing-of-7-0-million-private-placement-302727315.html

SOURCE Health In Tech Inc.

FAQ

How much did Health In Tech (HIT) raise in the March 27, 2026 PIPE-financing?

Health In Tech raised approximately $7.0 million in gross proceeds from the PIPE. According to the company, the financing came from institutional and accredited investors and is stated before placement agent fees and expenses.

How many shares did Health In Tech (HIT) issue and at what price in the PIPE?

The company issued 5,600,000 shares of common stock at $1.25 per share. According to the company, those figures reflect the aggregate shares and the per-share offering price.

What will Health In Tech (HIT) use the PIPE proceeds for after the March 27, 2026 closing?

Proceeds will fund expansion of sales distribution, advance technology development, support new product development, and general corporate purposes. According to the company, these are the stated intended uses of net proceeds.

Does the Health In Tech (HIT) PIPE place any resale restrictions on the new shares?

Yes. The securities were issued in a private placement and are not registered, so resale is restricted until an effective registration statement or applicable exemption. According to the company, registration rights were agreed with PIPE investors.

Who acted as placement agent and legal counsel for Health In Tech (HIT) in the PIPE?

Craig-Hallum Capital Group LLC served as sole placement agent, with Loeb & Loeb LLP counsel to the company and Faegre Drinker counsel to the placement agent. According to the company, those advisors worked on the transaction.